New oncology drugs and osteonecrosis of the jaw (ONJ).
Migliorati
Cesar A
CA
Department of Biologic and Diagnostic Sciences, University of Tennessee Health Sciences Center, College of Dentistry, USA.
Covington
J Stansill
JS
D020533:Angiogenesis Inhibitors / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000009:adverse effects; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents / Q000009:adverse effects*; D050071:Bone Density Conservation Agents / Q000009:adverse effects; D000069448:Denosumab; D004164:Diphosphonates / Q000009:adverse effects; D006801:Humans; D007571:Jaw Diseases / Q000209:etiology*; D010020:Osteonecrosis / Q000209:etiology*; D053245:RANK Ligand / Q000009:adverse effects
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D053245:RANK Ligand; D000069448:Denosumab